Clomiphene Citrate 50mg

Clomiphene citrate is a nonsteroidal Selective Estrogen Receptor Modulator (SERM) first approved by the FDA in 1967. It is the first-line oral therapy for ovulatory dysfunction in women who wish to become pregnant, and remains one of the most widely prescribed fertility medications worldwide because of its low cost, oral administration, and well-established safety profile relative to injectable options.

Marketed under the brand name Clomid, it is also used off-label in men with secondary hypogonadism (low testosterone caused by reduced pituitary signaling) as an alternative to testosterone replacement that does not suppress natural sperm production.

Clomiphene citrate is indicated for the induction of ovulation in anovulatory or oligo-ovulatory women with adequate endogenous estrogen production and normal liver function who desire pregnancy. It is typically the first medication tried before moving to injectable gonadotropins or IVF.

Off-label, it is used in men with secondary (hypogonadotropic) hypogonadism to raise endogenous testosterone by increasing the body's own LH and FSH output, rather than replacing testosterone directly.

Pharmacodynamics

Clomiphene citrate binds to estrogen receptors in the hypothalamus, blocking normal negative feedback from circulating estradiol. The hypothalamus interprets this as a low-estrogen state and increases the pulse frequency of gonadotropin-releasing hormone (GnRH), which in turn raises pituitary secretion of follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The resulting rise in FSH recruits and matures ovarian follicles, and the subsequent LH surge triggers ovulation, typically 5 to 10 days after the last dose.

Pharmacokinetics

• Absorption: Well absorbed after oral dosing.
• Distribution: Accumulates in fatty tissue and undergoes significant enterohepatic recirculation, giving it an unusually long elimination profile for an oral drug — trace amounts have been detected in the blood weeks after the last dose.
• Metabolism: Hepatic.
• Elimination: Predominantly fecal, with a terminal elimination half-life estimated at roughly 5 to 7 days on average, though individual clearance varies widely.

Standard Regimen

• Starting dose: 50 mg orally once daily for 5 days, usually beginning on cycle day 3, 4, or 5 (day 1 = first day of menstrual bleeding), as directed by your prescriber.
• Dose escalation: If ovulation does not occur, the dose may be increased to 100 mg/day for 5 days in a subsequent cycle. Doses above 100 mg/day are not typically used outside specialist supervision.
• Cycle limit: Most prescribers cap cumulative use around 6 treatment cycles; if pregnancy hasn't occurred by then, your provider will reassess and discuss other options.

Monitoring

Ovulation is typically confirmed with a urine ovulation-predictor kit 5–10 days after the last dose, basal body temperature charting, a mid-luteal-phase progesterone blood test, or ultrasound follicle tracking — your prescriber will tell you which method(s) they want you to use.

Common Side Effects

• Hot flashes / vasomotor symptoms (the most frequently reported side effect)
• Breast tenderness
• Bloating and mild ovarian enlargement or pelvic discomfort
• Mood changes or irritability
• Nausea and headache

Visual Disturbances

Blurred vision, seeing spots, or other visual symptoms occur in a small percentage of patients and are a reason to stop the medication and contact your prescriber for an eye evaluation before continuing treatment.

Multiple Pregnancy

Because clomiphene often matures more than one follicle per cycle, the chance of twins rises to roughly 7–10% (versus about 1–2% in the general population); higher-order multiples are uncommon.

Ovarian Hyperstimulation Syndrome (OHSS)

OHSS is far less common with clomiphene than with injectable gonadotropins, but ovarian enlargement and pelvic pain should be reported to your provider.

Formal drug-drug interaction studies are limited. Clomiphene is generally not combined with other ovulation-inducing agents within the same cycle except under direct fertility-specialist supervision. Because it is hepatically metabolized, use with caution in patients with liver disease. A pregnancy test confirming a negative result is required before starting each new treatment cycle.

Contraindications

• Pregnancy — clomiphene is contraindicated once pregnancy is confirmed and can cause fetal harm
• Liver disease or abnormal liver function
• Abnormal uterine bleeding of undiagnosed cause — should be evaluated before starting
• Ovarian cysts unrelated to polycystic ovary syndrome
• Known hormone-dependent tumors

Lactation

Clomiphene can reduce milk supply and is generally not recommended during breastfeeding; discuss timing with your provider if you are nursing.